HUP0000833A3 - Treatment of lupus nephritis with anti-cd40l compounds - Google Patents
Treatment of lupus nephritis with anti-cd40l compoundsInfo
- Publication number
- HUP0000833A3 HUP0000833A3 HU0000833A HUP0000833A HUP0000833A3 HU P0000833 A3 HUP0000833 A3 HU P0000833A3 HU 0000833 A HU0000833 A HU 0000833A HU P0000833 A HUP0000833 A HU P0000833A HU P0000833 A3 HUP0000833 A3 HU P0000833A3
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- lupus nephritis
- cd40l compounds
- cd40l
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3467397P | 1997-01-10 | 1997-01-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000833A2 HUP0000833A2 (en) | 2000-07-28 |
| HUP0000833A3 true HUP0000833A3 (en) | 2001-09-28 |
Family
ID=21877889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000833A HUP0000833A3 (en) | 1997-01-10 | 1997-12-31 | Treatment of lupus nephritis with anti-cd40l compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030031668A1 (https=) |
| EP (2) | EP0948355A1 (https=) |
| JP (1) | JP2001508441A (https=) |
| KR (2) | KR20000070034A (https=) |
| CN (2) | CN1247472A (https=) |
| AU (1) | AU5709798A (https=) |
| BR (1) | BR9714523A (https=) |
| CA (1) | CA2277222A1 (https=) |
| CZ (1) | CZ297680B6 (https=) |
| EA (2) | EA200501076A1 (https=) |
| EE (1) | EE9900273A (https=) |
| HU (1) | HUP0000833A3 (https=) |
| IL (1) | IL130784A0 (https=) |
| IS (1) | IS5100A (https=) |
| NO (1) | NO993274L (https=) |
| NZ (1) | NZ337072A (https=) |
| PL (1) | PL190663B1 (https=) |
| TR (7) | TR200001250T2 (https=) |
| WO (1) | WO1998030240A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| JP2002510643A (ja) * | 1998-04-03 | 2002-04-09 | トラスティーズ・オブ・ダートマス・カレッジ | 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用 |
| IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| MXPA01006006A (es) | 1998-12-14 | 2004-08-12 | Genetics Inst | Cadena receptora de citocina. |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
| US20010055593A1 (en) * | 2000-03-14 | 2001-12-27 | Joseph Sypek | Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| JP2004508420A (ja) * | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| PL3718564T3 (pl) | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| CN100369932C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人cd154单克隆抗体及其应用 |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| US20130310266A1 (en) * | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| CN120904322A (zh) | 2013-09-13 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN107921112A (zh) * | 2015-08-31 | 2018-04-17 | 默克专利有限公司 | 调节lgals3bp以治疗系统性红斑狼疮的方法 |
| KR102840867B1 (ko) | 2017-05-24 | 2025-07-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| WO1997026000A1 (en) * | 1996-01-16 | 1997-07-24 | The Trustees Of Columbia Univeristy In The City Of New York | Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________ |
| WO1997034473A1 (en) * | 1996-03-21 | 1997-09-25 | The Trustees Of Columbia University In The City Of New York | Craf1 (traf-3) isoforms and uses thereof |
-
1997
- 1997-12-31 CN CN97181948A patent/CN1247472A/zh active Pending
- 1997-12-31 JP JP53090198A patent/JP2001508441A/ja not_active Ceased
- 1997-12-31 CA CA002277222A patent/CA2277222A1/en not_active Abandoned
- 1997-12-31 CN CNA2004100353620A patent/CN1572325A/zh active Pending
- 1997-12-31 KR KR1019997006253A patent/KR20000070034A/ko not_active Ceased
- 1997-12-31 BR BR9714523-8A patent/BR9714523A/pt not_active Application Discontinuation
- 1997-12-31 CZ CZ0244499A patent/CZ297680B6/cs not_active IP Right Cessation
- 1997-12-31 TR TR2000/01250T patent/TR200001250T2/xx unknown
- 1997-12-31 EP EP97953325A patent/EP0948355A1/en not_active Withdrawn
- 1997-12-31 EA EA200501076A patent/EA200501076A1/ru unknown
- 1997-12-31 TR TR1999/02191T patent/TR199902191T2/xx unknown
- 1997-12-31 IL IL13078497A patent/IL130784A0/xx unknown
- 1997-12-31 EP EP03014404A patent/EP1357131A3/en not_active Withdrawn
- 1997-12-31 HU HU0000833A patent/HUP0000833A3/hu unknown
- 1997-12-31 NZ NZ337072A patent/NZ337072A/xx unknown
- 1997-12-31 TR TR2000/01249T patent/TR200001249T2/xx unknown
- 1997-12-31 KR KR1020057013113A patent/KR100618081B1/ko not_active Expired - Fee Related
- 1997-12-31 PL PL97334495A patent/PL190663B1/pl not_active IP Right Cessation
- 1997-12-31 TR TR2000/01251T patent/TR200001251T2/xx unknown
- 1997-12-31 TR TR2000/01246T patent/TR200001246T2/xx unknown
- 1997-12-31 TR TR2000/01247T patent/TR200001247T2/xx unknown
- 1997-12-31 EA EA199900636A patent/EA006314B1/ru not_active IP Right Cessation
- 1997-12-31 TR TR2000/01248T patent/TR200001248T2/xx unknown
- 1997-12-31 EE EEP199900273A patent/EE9900273A/xx unknown
- 1997-12-31 AU AU57097/98A patent/AU5709798A/en not_active Abandoned
- 1997-12-31 WO PCT/US1997/023482 patent/WO1998030240A1/en not_active Ceased
-
1999
- 1999-06-30 IS IS5100A patent/IS5100A/is unknown
- 1999-07-01 NO NO993274A patent/NO993274L/no not_active Application Discontinuation
-
2002
- 2002-09-27 US US10/260,639 patent/US20030031668A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/527,700 patent/US20070190053A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000833A3 (en) | Treatment of lupus nephritis with anti-cd40l compounds | |
| ZA982020B (en) | Treatment of effluent streams | |
| ZA983176B (en) | Therapeutic compounds | |
| SI0948541T1 (sl) | PTHrP analogi | |
| IL113248A0 (en) | Use of alpha - 1c specific compounds | |
| GB9701674D0 (en) | Use of organic compounds | |
| GB9725114D0 (en) | Treatment of pruritus | |
| GB9723258D0 (en) | Treatment of organic materials | |
| GB9616037D0 (en) | Treatment of solid containing material derived from effluent | |
| GB9716345D0 (en) | Therapeutic compounds | |
| HK1025041A (en) | Treatment of lupus nephritis with anti-cd40l compounds | |
| GB9716347D0 (en) | Therapeutic compounds | |
| GB9716344D0 (en) | Therapeutic compounds | |
| HK1023068A (en) | Treatment of iupus nephritis with anti-cd40l compounds | |
| GB2301353B (en) | Treatment of undesirable halogenated organic compounds | |
| GB2331514B (en) | Effluent treatment | |
| IL120955A0 (en) | Treatment of osteoporosis | |
| GB2365419B (en) | Treatment of effluents | |
| ZA9811524B (en) | Treatment of effluent | |
| GB9722026D0 (en) | Use of compounds | |
| GB9810855D0 (en) | Use of compounds | |
| GB2316942B (en) | Purification of pentafluoroethane | |
| HUP9902845A3 (en) | Novel treatment of leptine resistance | |
| PL327430A1 (en) | Set of shaped components | |
| GB9503795D0 (en) | Use of organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |